Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics

CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics

Published on: December 8, 2023

Functional DNAzyme-Guided Target Identification and Portable Detection of Colorectal Cancer.

Yu Yan¹, Hao Zheng¹, Shenyang Zhao²

¹State Key Laboratory of Synergistic Chem-Bio Synthesis, School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, the International Peace Maternity and Child Health Hospital, School of Medicine, National Center for Translational Medicine, Shanghai Jiao Tong University, Shanghai 200030, China.

|June 26, 2026

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Scalable and sustainable manufacturing of functional DNA nanoassemblies via self-folding circular single-stranded DNA.

Nature communications·2026

Same author

Generation of HBV cccDNA using single-stranded M13 phage DNA for authentic minichromosome functionality.

Journal of virology·2026

Same author

CRISPR/Cas-Based Biosensing Strategies for Non-Nucleic Acid Contaminants in Food Safety: Status, Challenges, and Perspectives.

Journal of agricultural and food chemistry·2025

Same author

A Label-Free CRISPR/Cas12a-G4 Biosensor Integrated with FTA Card for Detection of Foodborne Pathogens.

Biosensors·2025

Same author

Author Correction: R-loop-dependent promoter-proximal termination ensures genome stability.

Nature·2025

Same author

Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: A 12-year median follow-up study.

Clinical and translational medicine·2024

Same journal

DeepDOX1: A Dual-Drive Framework Integrating Deep Learning and First-Principles Quantum Chemistry for Drug-Protein Affinity Prediction.

JACS Au·2026

Same journal

Catalyst-Controlled Regiodivergent C-H Olefination of Furanyl Carbamates through a Rational Approach.

JACS Au·2026

Same journal

Charting the Biosynthetic Landscape of Hybrid Polyketide-Nonribosomal Peptide-Specialized Lipids.

JACS Au·2026

Same journal

Valence-State-Dependent Surface Lattice Oxygen in CeO<sub>2</sub>‑Modified VPO Catalysts: Elucidating the Mechanism of <i>n</i>‑Butane Selective Oxidation to Maleic Anhydride.

JACS Au·2026

Same journal

Quantitative Insights into Pressure-Dependent Mass Transport and Reaction Kinetics in Electrochemical CO<sub>2</sub> Reduction.

JACS Au·2026

Same journal

3‑Methylthiopropionic Acid Kills Carbapenem-Resistant <i>Klebsiella pneumoniae</i> by Disrupting Membrane Integrity and Bioenergetics.

JACS Au·2026

See all related articles

This summary is machine-generated.

Researchers identified malic enzyme 1 (ME1) as a colorectal cancer (CRC) activator for DNAzyme assays. This breakthrough enables rapid, instrument-free visual detection of CRC at the point of care.

Area of Science:

Biochemistry
Molecular Biology
Oncology

Background:

Rapid colorectal cancer (CRC) discrimination during tissue sampling is a significant clinical challenge.
DNAzyme assays offer selective analysis but are limited by unknown endogenous activators.

Purpose of the Study:

To identify the molecular activator of a DNAzyme selected against colorectal cancer tissue lysates.
To develop a rapid, instrument-free diagnostic platform for colorectal cancer detection.

Main Methods:

An iterative DNAzyme activity-guided isolation strategy combining chromatographic fractionation and affinity enrichment was employed.
The identified ME1-activated DNAzyme reaction was translated into a lateral flow assay for visual detection.

Main Results:

Keywords:

DNAzyme colorectal cancer malic enzyme 1 point-of-care diagnostics target identification

More Related Videos

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition

Published on: February 9, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics

CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics

Published on: December 8, 2023

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection

Published on: June 8, 2020

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition

DNAzyme 10-23 - Based Nanomachines for Nucleic Acid Recognition

Published on: February 9, 2024

Malic enzyme 1 (ME1) was identified as the specific activator for the colorectal cancer-targeting DNAzyme.
The developed lateral flow assay achieved instrument-free visual detection of CRC within 35 minutes.
The platform demonstrated high diagnostic accuracy, discriminating CRC from intraepithelial neoplasia with an AUC of 0.98 in clinical specimens.

Conclusions:

Defining the molecular basis of DNAzyme activation (ME1) enables the development of sensitive diagnostic tools.
The coupled DNAzyme activation and portable lateral flow readout provide a direct pathway for rapid, near-point-of-care CRC detection.